CERO THERAPEUTICS HOLDINGS, INC.
CERO · OTCMCIK 1870404fmd_1ZFPBF6RJ6ZQNM1S3WHSJTYXK5Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jun 08, 2021 to Jun 30, 2026, 19 periods
| Line item | FY2022 | FY2023 | FY2025 |
|---|---|---|---|
| Research and development | – | 5 | – |
| Total operating expenses | 3 | 8 | – |
| Operating income | (3) | (8) | – |
| Interest expense | – | (0) | – |
| Interest and investment income | 3 | 0 | – |
| Other non-operating income (expense) | – | 0 | – |
| Income before taxes | (0) | (2) | (20) |
| Income tax expense | 1 | 0 | – |
| Net income from continuing operations | (1) | (3) | – |
| Net income | (1) | (7) | (20) |
| Net income to common shareholders | – | (7) | – |